Europe's biggest privately-held biotech BioNTech has been in the news recently, with reports the company could be about to raise just shy of a billion dollars in a US listing.
“People familiar with the plan” told Reuters that two banks have already been hired to steer a listing on the Nasdaq exchange later this year, which would value the personalized medicine specialist at about $4 billion.
While press reports intimate that a listing is practically inevitable in the short term, chief operating officer Sean Marett is less certain the firm will go down this route.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze